Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study
Latest Information Update: 26 Oct 2023
Price :
$35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Salivary gland cancer
- Focus Therapeutic Use
- 24 Nov 2016 Status changed from active, no longer recruiting to completed as reported by results published in the European Journal of Cancer
- 04 Nov 2016 Results assessig safety and efficacy published in the European Journal of Cancer
- 05 Oct 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2010-020375-24).